Richard B Lipton1, Kristina M Fanning1, Daniel Serrano1, Michael L Reed1, Roger Cady1, Dawn C Buse2. 1. From Albert Einstein College of Medicine (R.B.L., D.S., D.C.B.), Bronx; Montefiore Headache Center (R.B.L., D.C.B.), Bronx, NY; Vedanta Research (K.M.F., D.S., M.L.R.), Chapel Hill, NC; and Headache Care Center (R.C.), Springfield, MO. 2. From Albert Einstein College of Medicine (R.B.L., D.S., D.C.B.), Bronx; Montefiore Headache Center (R.B.L., D.C.B.), Bronx, NY; Vedanta Research (K.M.F., D.S., M.L.R.), Chapel Hill, NC; and Headache Care Center (R.C.), Springfield, MO. dbuse@montefiore.org.
Abstract
OBJECTIVE: To test the hypothesis that ineffective acute treatment of episodic migraine (EM) is associated with an increased risk for the subsequent onset of chronic migraine (CM). METHODS: In the American Migraine Prevalence and Prevention Study, respondents with EM in 2006 who completed the Migraine Treatment Optimization Questionnaire (mTOQ-4) and provided outcome data in 2007 were eligible for analyses. The mTOQ-4 is a validated questionnaire that assesses treatment efficacy based on 4 aspects of response to acute treatment. Total mTOQ-4 scores were used to define categories of acute treatment response: very poor, poor, moderate, and maximum treatment efficacy. Logistic regression models were used to examine the dichotomous outcome of transition from EM in 2006 to CM in 2007 as a function of mTOQ-4 category, adjusting for covariates. RESULTS: Among 5,681 eligible study respondents with EM in 2006, 3.1% progressed to CM in 2007. Only 1.9% of the group with maximum treatment efficacy developed CM. Rates of new-onset CM increased in the moderate treatment efficacy (2.7%), poor treatment efficacy (4.4%), and very poor treatment efficacy (6.8%) groups. In the fully adjusted model, the very poor treatment efficacy group had a more than 2-fold increased risk of new-onset CM (odds ratio = 2.55, 95% confidence interval 1.42-4.61) compared to the maximum treatment efficacy group. CONCLUSION: Inadequate acute treatment efficacy was associated with an increased risk of new-onset CM over the course of 1 year. Improving acute treatment outcomes might prevent new-onset CM, although reverse causality cannot be excluded.
OBJECTIVE: To test the hypothesis that ineffective acute treatment of episodic migraine (EM) is associated with an increased risk for the subsequent onset of chronic migraine (CM). METHODS: In the American Migraine Prevalence and Prevention Study, respondents with EM in 2006 who completed the Migraine Treatment Optimization Questionnaire (mTOQ-4) and provided outcome data in 2007 were eligible for analyses. The mTOQ-4 is a validated questionnaire that assesses treatment efficacy based on 4 aspects of response to acute treatment. Total mTOQ-4 scores were used to define categories of acute treatment response: very poor, poor, moderate, and maximum treatment efficacy. Logistic regression models were used to examine the dichotomous outcome of transition from EM in 2006 to CM in 2007 as a function of mTOQ-4 category, adjusting for covariates. RESULTS: Among 5,681 eligible study respondents with EM in 2006, 3.1% progressed to CM in 2007. Only 1.9% of the group with maximum treatment efficacy developed CM. Rates of new-onset CM increased in the moderate treatment efficacy (2.7%), poor treatment efficacy (4.4%), and very poor treatment efficacy (6.8%) groups. In the fully adjusted model, the very poor treatment efficacy group had a more than 2-fold increased risk of new-onset CM (odds ratio = 2.55, 95% confidence interval 1.42-4.61) compared to the maximum treatment efficacy group. CONCLUSION: Inadequate acute treatment efficacy was associated with an increased risk of new-onset CM over the course of 1 year. Improving acute treatment outcomes might prevent new-onset CM, although reverse causality cannot be excluded.
Authors: R B Lipton; K Kolodner; M E Bigal; D Valade; M J A Láinez; J Pascual; A Gendolla; G Bussone; N Islam; K Albert; B Parsons Journal: Cephalalgia Date: 2009-02-23 Impact factor: 6.292
Authors: Dawn C Buse; Aubrey N Manack; Kristina M Fanning; Daniel Serrano; Michael L Reed; Catherine C Turkel; Richard B Lipton Journal: Headache Date: 2012-07-25 Impact factor: 5.887
Authors: Richard B Lipton; Marcelo E Bigal; Sait Ashina; Rami Burstein; Stephen Silberstein; Michael L Reed; Daniel Serrano; Walter F Stewart Journal: Ann Neurol Date: 2008-02 Impact factor: 10.422
Authors: Matthew S Robbins; M Cristina C Victorio; Mark Bailey; Calli Cook; Ivan Garza; J Stephen Huff; Duren Ready; Nathaniel M Schuster; David Seidenwurm; Elizabeth Seng; Christina Szperka; Erin Lee; Raissa Villanueva Journal: Headache Date: 2020-09-23 Impact factor: 5.887